Treatment for PMDD
Selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for premenstrual dysphoric disorder, with continuous paroxetine showing the greatest efficacy across all symptom domains 1, 2, 3.
First-Line Treatment: SSRIs
SSRIs are established as the primary pharmacologic intervention for PMDD based on the most robust evidence 2, 3, 4. The serotonergic system plays a central role in PMDD pathophysiology, making these agents particularly effective 5.
Dosing strategies include:
- Continuous daily dosing (throughout the entire cycle)
- Luteal phase dosing (starting mid-cycle and continuing through menses)
- Symptom-onset dosing (initiated when symptoms begin)
Among SSRIs, continuous paroxetine demonstrates superior efficacy across emotional, physical, and behavioral symptom domains 1. While all three dosing strategies work, continuous dosing provides the most consistent symptom control, though luteal phase dosing may be preferred by patients seeking intermittent treatment 2.
Other effective serotoninergic agents include venlafaxine and duloxetine (SNRIs), which serve as alternatives if SSRIs are not tolerated 2, 3.
Second-Line Treatment: Combined Oral Contraceptives
For patients who fail SSRI therapy or prefer hormonal management, combined oral contraceptives containing drospirenone in a 24/4 regimen (24 active pills, 4 placebo days) are the most effective option 1, 6, 3. This is the only FDA-approved hormonal contraceptive specifically for PMDD treatment 6.
The drospirenone/ethinyl estradiol 24/4 formulation shows particular efficacy for both physical and emotional symptoms 1. The extended active pill regimen (24 days versus traditional 21 days) reduces hormone-free intervals and provides better symptom control 6.
Treatment Selection Algorithm
Choose SSRIs when:
- Predominant symptoms are emotional (irritability, mood swings, anger, depression)
- Patient has no contraindications to antidepressants
- Contraception is not desired or needed
Choose drospirenone-containing COCs when:
- Patient desires contraception
- Physical symptoms (bloating, breast tenderness) are prominent alongside emotional symptoms
- Patient prefers hormonal over psychotropic medication
- No contraindications to estrogen exist
Third-Line and Refractory Cases
For patients who fail both SSRIs and COCs 3, 4:
GnRH agonists with add-back hormone therapy provide ovulation suppression and demonstrate efficacy but are limited by cost, side effects, and bone density concerns 2, 4.
Surgical management (bilateral oophorectomy with hysterectomy) is reserved for severe, treatment-refractory PMDD with completed childbearing, as it provides definitive cure by eliminating hormonal fluctuations 3, 4.
Adjunctive and Alternative Treatments
Calcium supplementation (1200 mg daily) is the only supplement with consistent evidence of therapeutic benefit and should be considered as adjunctive therapy 2, 3.
Other anxiolytics like alprazolam and buspirone show efficacy but are considered secondary options due to dependence concerns 2.
Cognitive-behavioral therapy demonstrates benefit and can be combined with pharmacotherapy for enhanced outcomes 5, 3.
Critical Pitfalls to Avoid
- Do not treat PMDD as major depressive disorder - while both respond to SSRIs, PMDD has distinct pathophysiology involving progesterone metabolites and GABA-A receptor sensitivity 5
- Ensure prospective symptom charting confirms luteal phase timing and menstrual remission before initiating treatment 7, 3
- Avoid progestin-only contraceptives - these may worsen symptoms; only combined formulations with drospirenone are indicated 6
- Do not delay treatment escalation - if first-line therapy fails after 2-3 cycles, move to alternative agents rather than prolonging ineffective treatment 3